Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy
Interventional
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The goal of this study is to determine the safety of pharmacogenetic guided dosing of epirubicin for each UGT2B7 genotype.
Primary Objectives To describe the side effects of pharmacogenetically individualized FEC chemotherapy in the adjuvant and neoadjuvant treatment of breast cancer.
10 years
Yes
Michael B Sawyer, MD FRCPC BScPharm
Principal Investigator
Alberta Health Services
Canada: Health Canada
FEC100-01
NCT01740271
December 2012
June 2025
Name | Location |
---|